The last of the triumvirate is romosozumab, the drug for post-menopausal osteoporosis being co-developed with Amgen ... now sell alongside its own neurology products, plus a number of future ...

Amgen (Thousand Oaks ... that more than doubled their IPO offer price over the year included the following: neurology company Acorda Therapeutics (Hawthorne, NY, USA), whose stock price was ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

New Delhi, Jan. 17, 2025 (GLOBE NEWSWIRE) -- The global pharma & biotech CRM software market was valued at US$ 7.21 billion IN 2024 and is projected to reach US$ 20.0 by 2033 at a CAGR of 15.2% during ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...

Jefferies analyst Michael Yee maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $350.00. The company’s shares closed yesterday at $267.10. Discover ...

His career has included stops at Eli Lilly, Novian Health and, for the last 16 years, Amgen. His tenure at Amgen included roles in sales and marketing for many of its hematology and oncology ...

To gain a panoramic view of Amgen's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.